Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report

Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial growth factors have provided the basis for improved outcomes in select patients with unresectable or metastatic hepatocellular carcinoma. However, for patients with resectable disease, surgery alone or an orthotopi...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelrahim, Maen, Esmail, Abdullah, Umoru, Godsfavour, Westhart, Kiersten, Abudayyeh, Ala, Saharia, Ashish, Ghobrial, Rafik M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221586/
https://www.ncbi.nlm.nih.gov/pubmed/35735450
http://dx.doi.org/10.3390/curroncol29060341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221586/
https://www.ncbi.nlm.nih.gov/pubmed/35735450
http://dx.doi.org/10.3390/curroncol29060341

Ejemplares similares